Heckers, S., Zalesak, M., Weiss, A
These oral drugs also present new PA considerations: payers may need to decide whether patients can switch between oral and injectable formulations without restarting the PA process
Within this context, it is not surprising that a great deal of inhibitors and pro-drugs targeting GSTs have been synthesized and tested so far, with new scaffolds or analogues being reported every year
Paxlovid (nirmatrelvir/ritonavir) Disease area(s): Infectious diseases (antivirals) Manufacturer(s): Pfizer 2024 Sales (USD): $5.72 billion Why it sold so well: In 2024, Pfizers COVID-19 antiviral treatment, Paxlovid, generated $5.72 billion in global revenue, making it the companys third-highest-selling product for the year
Liposomal glutathione uses a phospholipid delivery strategy
The results from Voluma are immediately noticeable and can last for up to two years